Alexion Reports Disappointing Phase II Data on Soliris
Alexion Pharmaceuticals, Inc. ( ALXN ) reported disappointing data from a phase II study evaluating Soliris (eculizumab) for the prevention of antibody mediated rejection (AMR) in living-donor kidney transplant recipients requiring desensitization. […]